cuv
CUV: Biotech Profit Pioneer - Vitiligo's Victory Could Be Transformational
Updated 8 Oct 2025
Profitable biotech rarity with 90% EPP monopoly and transformational vitiligo opportunity. Fair value $19.94 vs current $10.89 implies 83% upside. Quality score 7.9/10.
View note